<DOC>
	<DOC>NCT01150942</DOC>
	<brief_summary>To assess the immunogenicity and safety of the vero cell-derived inactivated JE vaccine in Korean healthy children aged 12~23 months</brief_summary>
	<brief_title>Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea</brief_title>
	<detailed_description>To compare the Vero cell-derived inactivated Japanese encephalitis(JE) vaccine 'KD-287(JEIMMUGEN INJ.)' with the mouse brain-derived inactivated JE vaccine in terms of the immunogenicity and safety, in Korean healthy children aged 12~23 months</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy children aged 1223 months Written informed consent History of documented HIV Known or suspected impairment of immunologic function History of serious chronic disease Received any JE vaccine prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>JEV</keyword>
	<keyword>vero cell</keyword>
</DOC>